Korean Circ J.  2025 Mar;55(3):215-227. 10.4070/kcj.2024.0222.

Increasing Very Low-Dose Edoxaban Prescription: Effectiveness and Safety Data of Korean AF Patients

• Choi J
• Yang SY
• Lee SR
• Cho MS
• Lee KY
• Ahn HJ
• Kwon S
• Cha MJ
• Kim J
• Nam GB
• Choi KJ
• Choi EK
• Oh S
• Lip GYH

• KMID: 2565813
• DOI: http://doi.org/10.4070/kcj.2024.0222

Abstract

Background and Objectives
Evidence remains limited on the real-world prescription of very low-dose oral anticoagulation among frail patients with atrial fibrillation (AF). We described the practice patterns, effectiveness, and safety of very low-dose edoxaban (15 mg once daily).
Methods
Patients with AF prescribed edoxaban 15 mg once daily in 2 tertiary hospitals between 2016 and September 2022 were included. Baseline clinical characteristics and clinical outcomes of interest were thromboembolic and bleeding events.
Results
A total of 674 patients were included (mean age 78.3±9.1, 49.7% aged ≥80 years, 49.3% women, median follow-up 1.0±1.2 years). Mean CHA 2 DS 2 -VASc score was 3.9±1.6, and the modified HAS-BLED score was 2.0±1.1. Between 2016 and 2022, the number of very lowdose edoxaban prescriptions increased. The main reasons for the prescription of very lowdose were low body weight (55.5% below 60 kg), anaemia (62.8%), chronic kidney disease (40.2%), active cancer (15.3%), concomitant anti-platelet use (26.7%), and prior major bleeding (19.7%). During a median follow-up duration of 8 (interquartile range 3–16) months, overall thromboembolic and bleeding events occurred in 16 (2.3%) and 88 (13.1%) patients, respectively. Compared to the expected event rates on the established risk scoring systems, patients receiving very low-dose edoxaban demonstrated a 61% reduction in ischemic stroke, a 68% reduction of ischemic stroke/transient ischemic attack/systemic embolism, whereas a 49% increase in major bleeding.
Conclusions
The prescription of very low-dose edoxaban was increased over time, attributable to various clinical factors. The use of very low-dose edoxaban reduced the expected risk of thromboembolic events.

Keyword

Atrial fibrillation; Factor Xa inhibitor; Off-label use; Stroke; Bleeding

Figure

• 

  Figure 1 Study flow. Total 674 patients who were prescribed edoxaban 15 mg once daily for stroke prevention in AF was enrolled from SNUH and AMC.AF = atrial fibrillation; AMC = Asan Medical Center; SNUH = Seoul National University Hospital.

• 

  Figure 2 The temporal trend of edoxaban 15 mg prescription. The prescription of very low-dose edoxaban increased over time in Korea, with a substantial rise observed after landmark events.AF = atrial fibrillation; ELDERCARE-AF = Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients; KFDA = Korean Food and Drug Administration; KHRS = Korean Heart Rhythm Society; RCT = randomized clinical trial.

• 

  Figure 3 Expected risk versus actual rate. Based on the CHA2DS2-VASc score, the RRR for ischemic stroke was 61%, and 68% for stroke/TIA/SE. According to the modified HAS-BLED score, there was a 49% increase in the relative risk of major bleeding.RRI = relative risk increase; RRR = relative risk reduction; SE = systemic embolism; TIA = transient ischemic attack.*Modified HAS-BLED score used.

• 

  Figure 4 In Korean practice, very low-dose edoxaban increased over time with low body weight, anaemia, chronic kidney disease, active cancer, concomitant antiplatelet agents, and prior major bleeding as the main cause. The use of very low-dose edoxaban reduced the expected risk of thromboembolic events.AF = atrial fibrillation; AMC = Asan Medical Center; ELDERCARE-AF = Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients; KFDA = Korean Food and Drug Administration; KHRS = Korean Heart Rhythm Society; SE = systemic embolism; SNUH = Seoul National University Hospital; TIA = transient ischemic attack.

Reference

1. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2024; 149:e1–e156. PMID: 38033089.

2. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021; 42:373–498. PMID: 32860505.

3. Chao TF, Joung B, Takahashi Y, et al. 2021 Focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: executive summary. Thromb Haemost. 2022; 122:20–47. PMID: 34773920.

4. Zhang XL, Zhang XW, Wang TY, et al. Off-label under- and overdosing of direct oral anticoagulants in patients with atrial fibrillation: a meta-analysis. Circ Cardiovasc Qual Outcomes. 2021; 14:e007971. PMID: 34932377.

5. Ruff CT, Giugliano RP, Braunwald E, et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015; 385:2288–2295. PMID: 25769361.

6. Steffel J, Ruff CT, Yin O, et al. Randomized, double-blind comparison of half-dose versus full-dose edoxaban in 14,014 patients with atrial fibrillation. J Am Coll Cardiol. 2021; 77:1197–1207. PMID: 33663737.

7. Okumura K, Akao M, Yoshida T, et al. Low-dose edoxaban in very elderly patients with atrial fibrillation. N Engl J Med. 2020; 383:1735–1745. PMID: 32865374.

8. Romiti GF, Proietti M, Bonini N, et al. Clinical complexity domains, anticoagulation, and outcomes in patients with atrial fibrillation: a report from the GLORIA-AF Registry phase II and III. Thromb Haemost. 2022; 122:2030–2041. PMID: 36037828.

9. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010; 137:263–272. PMID: 19762550.

10. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138:1093–1100. PMID: 20299623.

11. Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016; 5:e003725. PMID: 27412905.

12. Lip GYH, Skjøth F, Nielsen PB, Kjældgaard JN, Larsen TB. The HAS-BLED, ATRIA, and ORBIT bleeding scores in atrial fibrillation patients using non-vitamin K antagonist oral anticoagulants. Am J Med. 2018; 131:574.e13–574.e27.

13. Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021; 23:1612–1676. PMID: 33895845.

14. Chao TF, Chan NY, Chan YH, et al. Direct oral anticoagulant dosing in patients with atrial fibrillation: an asian perspective. JACC Asia. 2023; 3:707–723. PMID: 38095007.

15. Steinberg BA, Shrader P, Thomas L, et al. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II Registry. J Am Coll Cardiol. 2016; 68:2597–2604. PMID: 27978942.

16. Lee SR, Lee YS, Park JS, et al. Label adherence for non-vitamin K antagonist oral anticoagulants in a prospective cohort of Asian patients with atrial fibrillation. Yonsei Med J. 2019; 60:277–284. PMID: 30799590.

17. Guenoun M, Cohen S, Villaceque M, et al. Characteristics of patients with atrial fibrillation treated with direct oral anticoagulants and new insights into inappropriate dosing: results from the French National Prospective Registry: PAFF. Europace. 2023; 25:euad302. PMID: 37801642.

18. Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol. 2017; 69:2779–2790. PMID: 28595692.

19. Chan YH, Chao TF, Chen SW, et al. Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation. Heart Rhythm. 2020; 17:2102–2110. PMID: 32702416.

20. Arashi H, Yamaguchi J, Hagiwara N, et al. Rivaroxaban underdose for atrial fibrillation with stable coronary disease: the AFIRE trial findings. Thromb Haemost. 2022; 122:1584–1593. PMID: 35697255.

21. Yoshida T, Nakamura A, Funada J, et al. Efficacy and safety of edoxaban 15 mg according to renal function in very elderly patients with atrial fibrillation: a subanalysis of the ELDERCARE-AF trial. Circulation. 2022; 145:718–720. PMID: 35226559.

22. Akao M, Yamashita T, Fukuzawa M, Hayashi T, Okumura K. Efficacy and safety of low-dose edoxaban by body weight in very elderly patients with atrial fibrillation: a subanalysis of the randomized ELDERCARE-AF trial. J Am Heart Assoc. 2024; 13:e031506. PMID: 38240204.

23. Kuroda M, Tamiya E, Nose T, et al. Effect of 15-mg edoxaban on clinical outcomes in 3 age strata in older patients with atrial fibrillation: a prespecified subanalysis of the ELDERCARE-AF randomized clinical trial. JAMA Cardiol. 2022; 7:583–590. PMID: 35416910.

24. Chan YH, Chao TF, Chen SW, et al. Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral anticoagulants: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. 2023; 9:681–691. PMID: 37580139.

25. Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol. 2017; 14:627–628. PMID: 28960189.

26. Lip GYH, Genaidy A, Tran G, Marroquin P, Estes C, Sloop S. Improving stroke risk prediction in the general population: a comparative assessment of common clinical rules, a new multimorbid index, and machine-learning-based algorithms. Thromb Haemost. 2022; 122:142–150. PMID: 33765685.

27. Zheng Y, Li S, Liu X, Lip GY, Guo L, Zhu W. Effect of oral anticoagulants in atrial fibrillation patients with polypharmacy: a meta-analysis. Thromb Haemost. 2023; [Epub ahead of print].

28. Treewaree S, Lip GY, Krittayaphong R. Non-vitamin K antagonist oral anticoagulant, warfarin, and ABC pathway adherence on hierarchical outcomes: win ratio analysis of the COOL-AF Registry. Thromb Haemost. 2024; 124:69–79. PMID: 37625457.

29. Romiti GF, Pastori D, Rivera-Caravaca JM, et al. Adherence to the ‘atrial fibrillation better care’ pathway in patients with atrial fibrillation: impact on clinical outcomes-a systematic review and meta-analysis of 285,000 patients. Thromb Haemost. 2022; 122:406–414. PMID: 34020488.